This research article describes a novel "TCR turbocharging" pipeline designed to enhance the effectiveness of T cell receptors used in cancer immunotherapy. Scientists focused on a specific receptor, TCR156, which targets a prostate cancer antigen but naturally lacks the strength to eliminate tumors due to immune tolerance. By engineering specialized interactions called catch bonds, which strength...去小宇宙查看完整单集简介
前往小宇宙评论区与主播互动